文献速递胸部肿瘤放疗姑息放疗与转移瘤

广泛期小细胞肺癌巩固性胸部放疗后预防性颅脑照射的真实世界结局

Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-01-07

本回顾性研究纳入2013—2021年在本机构接受巩固性胸部放疗且无脑转移的广泛期小细胞肺癌患者47例,其中27例(57.4%)接受预防性颅脑照射、20例(42.6%)仅接受巩固性胸部放疗。预防性颅脑照射组中位总生存为19.2个月,未接受组为10.8个月(P=0.0334),脑失败风险降低(HR=0.22 [0.09-0.52],P=0.0004)。多因素分析显示预防性颅脑照射与总生存改善(HR=0.39 [0.19-0.80],P=0.01)及脑失败减少(HR=0.20 [0.09-0.44],P<0.001)独立相关。

要点

  • 接受预防性颅脑照射组中位总生存19.2个月,未接受组10.8个月(P=0.0334)。
  • 预防性颅脑照射与脑失败风险降低相关(HR=0.22 [0.09-0.52],P=0.0004)。
  • 多因素分析中预防性颅脑照射与总生存改善独立相关(HR=0.39 [0.19-0.80],P=0.01)。

核心结论

  • 本真实世界研究发现,在接受巩固性胸部放疗的广泛期小细胞肺癌患者中,预防性颅脑照射与总生存改善及脑失败减少独立相关,包括在化疗后脑MRI再分期后。
  • 预防性颅脑照射联合巩固性胸部放疗的作用应在前瞻性研究中评估。

研究设计与样本

  • 本机构2013—2021年接受巩固性胸部放疗且无脑转移的广泛期小细胞肺癌患者的回顾性分析。
  • 47例符合纳入标准且理论上适合预防性颅脑照射,27例(57.4%)接受预防性颅脑照射联合巩固性胸部放疗,20例(42.6%)仅接受巩固性胸部放疗。
  • 采用Kaplan-Meier法和累积发生率函数估计总生存和脑失败发生率,采用多因素Cox或Fine-Gray比例风险回归分析确定预防性颅脑照射与总生存的关联。

主要发现

  • 除年龄外基线特征相似,接受预防性颅脑照射者更年轻(中位年龄62岁),未接受者中位年龄72岁。
  • 接受预防性颅脑照射组中位总生存为19.2个月,未接受组为10.8个月(P=0.0334)。
  • 在化疗后接受MRI再分期的患者中,预防性颅脑照射带来的总生存改善仍然明显(P=0.0245)。
  • 预防性颅脑照射使脑失败减少(HR=0.22 [0.09-0.52],P=0.0004)。
  • 多因素分析中,预防性颅脑照射与总生存改善显著且独立相关(HR=0.39 [0.19-0.80],P=0.01),与脑失败减少显著且独立相关(HR=0.20 [0.09-0.44],P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出预防性颅脑照射联合巩固性胸部放疗的作用应在前瞻性研究中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of prophylactic cranial irradiation (PCI) is not well-defined in extensive-stage SCLC (ES-SCLC), with conflicting results from randomized trials and a lack of relevant data for patients who received consolidative thoracic radiotherapy (CTRT). We sought to evaluate the impact of PCI on the outcomes of ES-SCLC patients who were all treated with CTRT. METHODS: A retrospective analysis of ES-SCLC patients without brain metastases who were all treated with CTRT between 2013-2021 at our institution was conducted. Overall survival (OS) and incidence of brain failure (BFR) were estimated using Kaplan-Meier estimation and cumulative incidence function. Multivariable Cox or Fine-Gray's proportional hazard regression analysis (MVA) were performed to determine association between PCI and OS. RESULTS: 47 patients met inclusion criteria and were theoretically eligible for PCI, 27 (57.4 %) received PCI and CTRT while 20 (42.6 %) received CTRT alone. Baseline characteristics were similar except for age, where patients receiving PCI were younger (median age 62) compared to patients who did not receive PCI (median age 72). Median OS with PCI was 19.2 months, compared to 10.8 months without PCI (P = 0.0334). This improved OS remained apparent in patients who received post-chemotherapy MRI restaging (P = 0.0245). BFR was reduced with PCI (HR = 0.22 [0.09-0.52], P = 0.0004). On MVA, PCI was significantly and independently associated with improved OS (HR = 0.39 [0.19-0.80], P = 0.01) and reduced BFR (HR = 0.20 [0.09-0.44], P = < 0.001). CONCLUSION: This real-world study found PCI was independently associated with improved OS and reduced BFR in ES-SCLC patients treated with CTRT compared to patients treated with CTRT not receiving PCI, including after post-chemotherapy brain MRI. The role of PCI with CTRT should be evaluated in prospective studies.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lone AH, Salunkhe R, Sugumar V, et al. Real-world outcomes of prophylactic cranial irradiation utilization and efficacy for patients with extensive-stage small cell lung cancer treated with consolidative thoracic radiotherapy. Clin Transl Radiat Oncol. 2025. PMID: 39898331. doi:10.1016/j.ctro.2025.100917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。